Nilotinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of chronic myeloid leukemia (CML). It is a second-generation TKI and works by inhibiting the BCR-ABL protein, which is produced by the Philadelphia chromosome abnormality associated with CML.
